Skip to main content

HER2

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

RemeGen
RemeGenChina - Yantai
1 program
Disitamab VedotinN/AADC1 trial
Active Trials
NCT05649163Unknown306Est. May 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
RemeGenDisitamab Vedotin

Clinical Trials (1)

Total enrollment: 306 patients across 1 trials

NCT05649163RemeGenDisitamab Vedotin

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Start: Jan 2023Est. completion: May 2025306 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.